

ANSWERING REVIEWERS



May 12, 2014

Dear Editor,

Please find enclosed the edited manuscript in Word format (file name: 10300-review.doc).

Title: Effects of GLP-1 receptor agonists on non-alcoholic fatty liver disease

Author: Xing-chun Wang, Aaron M Gusdon, Huan Liu, Shen Qu.

Name of Journal: *World Journal of Gastroenterology*

ESPS Manuscript NO: 10300

The manuscript has been improved according to the suggestions of reviewers:

1 Format has been updated

2 Revision has been made according to the suggestions of the reviewer

Reviewer of **00503575**

(1) In the introduction, the authors claimed "We modified GLP-1 to Glucagon-like peptide-1 receptor agonists (GLP-1RA), which has a prolonged half-life and can be administered on a once daily basis [3]." This reference did not refer to a work done by the authors.

Thank you for pointing out the question. We accepted the suggestion and revised this sentence as following: The modified GLP-1 which also called Glucagon-like peptide-1 receptor agonists (GLP-1RA) has a prolonged half-life and can be administered on a once daily basis.

(2) In addition, the GLP-1RA can enhance insulin sensitivity, promote insulin secretion, and reduce lipid metabolism indirectly." This sentence needs a reference.

Thank you for pointing out the question. We accepted the suggestion and revised as following: In addition, the GLP-1RA can enhance insulin sensitivity, promote insulin secretion, and reduce lipid metabolism indirectly [15]-[17].

(3) GLP-1RA changed body composition, as patients treated with liraglutide showed a decrease in total body mass and total fat mass and the loss in fat mass accounted for most of the loss of total body mass [24]. "This sentence need to be reformulated. ?

Thank you for pointing out the question. We accepted the suggestion and revised as following: GLP-1RA treatment changed body composition, as patients who were treated with liraglutide showed a decrease in total body mass, and the majority of the total body mass that was lost was fat mass

(4) The citation of authors et al need to be re-verified through the text. The position of references [] need to be re-verified through the text. For example:

- in page 6: ovoid to mention the authors initials in the text such as in Sathyanarayana P et al...
- in page 7 Nitika A. Gupta et al [35] should be Gupta et al.
- In page 7 the mention of references ^[36] ^[39] should be ^[36,39].

Thank you for pointing out the question. We accepted the suggestion and revised as following: Nitika A. Gupta et al has been revised as Gupta et al. ^[36] ^[39] has been revised to ^[36,39]. Sathyanarayana P et al has benn revised to Padma et al.

(5) the sentence “NAFLD can progress from simple fatty liver fatty hepatitis to fatty liver fibrosis and fatty liver cirrhosis.”, the word fatty has been used 4 times

Thank you for pointing out the question. We accepted the suggestion and revised as following :NAFLD can progress from simple fatty liver to hepatitis and liver cirrhosis.

(6) The GLP-1 receptor agonist should be abbreviated through the text.

(7) Thank you for pointing out the question. We accepted the suggestion and GLP-1 receptor agonist has been abbreviated through the text.

Reviewer of **01551804**

(1) The authors described the epidemiology of NAFLD in the “Conclusions”; however, this should be included in the “Introduction”

Thank you for pointing out the question. We accepted the suggestion and described the epidemiology of NAFLD in the “Introduction” instead of in the “Conclusions”.

(2) Although the complicated mechanisms were summarized well in detail in the text, they should use figures to let the readers understand them more correctly.

Thank you for pointing out the question. We accepted the suggestion and used figures in this article.

Reviewer of **00503618**

(1) The first is a disclosure by the authors that they have no relationship with any of the manufacturers that produce GLP-1 receptor agonists.

We accepted the suggestion and declare that we have no relationship with any of the manufacturers that produce GLP-1 receptor agonists.

(2) The second missing item is a table that summarizes all of these important findings

(3) Thanks for the advice. We have added a figure that summarizes all of these important findings.

Thank you again for publishing our manuscript in the *World Journal of Gastroenterology*.

Sincerely yours,

Xing-chun Wang

Department of Endocrinology and Metabolism

Shanghai 10th People's Hospital

Shanghai200072, China

Fax: : +86-021-66302531

E-mail: 13916674766@163.com